The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Xilio Therapeutics Inc shares valued at $30,870 were purchased by Shannon James Samuel on Jun 16 ’25. At $0.69 per share, Shannon James Samuel acquired 45,000 shares. The insider’s holdings grew to 45,000 shares worth approximately $29700.0 following the completion of this transaction.
Also, Shannon James Samuel purchased 25,000 shares, netting a total of over 17,215 in proceeds. Following the buying of shares at $0.69 each, the insider now holds 70,000 shares.
Before that, Russo Rene had added 36,289 shares to its account. In a trade valued at $24,680, the PRESIDENT AND CEO bought Xilio Therapeutics Inc shares for $0.68 each. Upon closing the transaction, the insider’s holdings increased to 36,289 shares, worth approximately $0.19 million.
As published in their initiating research note from Chardan Capital Markets on December 21, 2022, Xilio Therapeutics Inc [XLO] has been a Buy and the price target has been revised to $7. Analysts at H.C. Wainwright started covering the stock with ‘”a Buy”‘ outlook in a report released in early January. As of November 16, 2021, Raymond James has initiated its “an Outperform” rating for XLO. Earlier on November 16, 2021, Morgan Stanley initiated its rating. Their recommendation was “an Overweight” for XLO stock.
Analyzing XLO Stock Performance
On last trading session,, Xilio Therapeutics Inc [NASDAQ: XLO] plunged -0.68% to $0.66. During the last five days, there has been a drop of approximately -4.68%. Over the course of the year, Xilio Therapeutics Inc shares have dropped approximately -30.83%. Shares of the company reached a 52-week high of $1.7000 on 02/12/25 and a 52-week low of $0.6200 on 04/07/25.
Support And Resistance Levels for Xilio Therapeutics Inc (XLO)
According to the 24-hour chart, there is a support level at 0.6504, which, if violated, would cause prices to drop to 0.6402. In the upper region, resistance lies at 0.6804. The next price resistance is at 0.7002. RSI (Relative Strength Index) is 41.73 on the 14-day chart, showing neutral technical sentiment.
Which companies own the most shares of Xilio Therapeutics Inc (XLO)?
In terms of Xilio Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 7 in the next 12 months, up nearly 944.78% from the previous closing price of $0.67. Analysts anticipate Xilio Therapeutics Inc stock to reach 7 by 2025, with the lowest price target being 7. In spite of this, 1 analysts ranked Xilio Therapeutics Inc stock as Buy at the end of 2025. On November 16, 2021, Guggenheim assigned a price target of “a Buy” to the stock and initiated coverage with a $40.
